专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110177068A1 PHARMACEUTICAL PREPARATION COMPRISING AN ANTIBODY AGAINST THE EGF RECEPTOR 审中-公开
标题翻译：包含抗EGF受体抗体的药物制剂
公开(公告)号：US20110177068A1
公开(公告)日：2011-07-21
申请号：US13070952
申请日：2011-03-24
申请人： Robert MUELLER , Hanns-Christian Mahler
发明人： Robert MUELLER , Hanns-Christian Mahler
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K47/10 , A61K9/0019 , A61K39/39591 , A61K47/02 , A61K47/12 , A61K47/183 , A61K47/26 , C07K16/2863 , C07K2317/24
摘要： The invention relates to an aqueous pharmaceutical preparation comprising an antibody against endothelial growth factor receptor (EGF receptor). The preparation has increased storage stability, even at elevated temperatures, and can be used for the treatment of tumours.
摘要翻译：本发明涉及包含抗内皮生长因子受体（EGF受体）抗体的水性药物制剂。该制剂即使在升高的温度下也具有增加的储存稳定性，并可用于治疗肿瘤。

2. 发明申请

US20110070225A1 Beta antibody parenteral formulation 审中-公开
标题翻译： β抗体肠胃外制剂
公开(公告)号：US20110070225A1
公开(公告)日：2011-03-24
申请号：US12448190
申请日：2007-12-11
申请人： Pierre Goldbach , Hanns-Christian Mahler , Robert Mueller , Christine Wurth
发明人： Pierre Goldbach , Hanns-Christian Mahler , Robert Mueller , Christine Wurth
IPC分类号： A61K39/395 , A61P25/28
CPC分类号： A61K39/39591 , A61K9/0019 , A61K9/19 , A61K47/183 , A61K47/26 , C07K16/18 , C07K2317/56
摘要： The present invention relates to a stable pharmaceutical parenteral formulation of an antibody, antibody molecule, a mixture of antibodies and/or a mixture of antibody molecules against the amyloid-beta peptide (Abeta) and a process for the preparation. Furthermore, corresponding uses are described.
摘要翻译：本发明涉及针对淀粉样蛋白-β肽（Abeta）的抗体，抗体分子，抗体混合物和/或抗体分子混合物的稳定药物非肠道制剂及其制备方法。此外，描述了相应的用途。

3. 发明申请

US20090208509A1 Pharmaceutical formulation of an antibody against IL-1R 审中-公开
标题翻译：抗IL-1R抗体的药物制剂
公开(公告)号：US20090208509A1
公开(公告)日：2009-08-20
申请号：US12284098
申请日：2008-09-18
申请人： Hanns-Christian Mahler , Robert Mueller , Christine Wurth
发明人： Hanns-Christian Mahler , Robert Mueller , Christine Wurth
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/92
摘要： Pharmaceutical formulation of an antibody against IL-1R (interleukin-1 receptor), a process for the preparation and uses of the formulation.
摘要翻译：针对IL-1R（白细胞介素-1受体）的抗体的药物制剂，该制剂的制备和用途的方法。

4. 发明申请

US20110236391A1 METHOD FOR OBTAINING AN EXCIPIENT-FREE ANTIBODY SOLUTION 审中-公开
标题翻译：获得无特殊抗体溶液的方法
公开(公告)号：US20110236391A1
公开(公告)日：2011-09-29
申请号：US13132809
申请日：2009-12-03
申请人： Hanns-Christian Mahler , Robert Mueller
发明人： Hanns-Christian Mahler , Robert Mueller
IPC分类号： A61K39/395
CPC分类号： C07K16/065 , A61K39/39591 , C07K16/18 , C07K16/22 , C07K16/3092
摘要： The present invention relates to a method of ultra- and dialfiltrating an antibody solution containing at least one solute in addition to the antibody, which comprises diafiltrating the antibody solution with a solvent and bringing said mixture into contact with a semi-permeable membrane so as to allow the at least one solute present in the antibody solution and having a molecular weight lower than the molecular weight cut-off of the membrane to pass through the membrane, whilst retaining the antibody so that a modified antibody solution is obtained that only contains the antibody and the solvent.
摘要翻译：本发明涉及除了抗体之外还含有至少一种溶质的抗体溶液的超滤和渗透方法，该方法包括用溶剂渗透抗体溶液并使所述混合物与半透膜接触，以便允许抗体溶液中存在的至少一种溶质并且具有低于膜的分子量截止值的分子量通过膜，同时保留抗体，使得获得仅含有抗体的修饰的抗体溶液和溶剂。

5. 发明申请

US20050220786A1 Lyophilised preparation comprising antibodies against the efg receptor 审中-公开
标题翻译：包含针对efg受体的抗体的冻干制剂
公开(公告)号：US20050220786A1
公开(公告)日：2005-10-06
申请号：US10499569
申请日：2002-11-25
申请人： Hanns-Christian Mahler , Hans-Peter Zobel , Robert Mueller , Christiane Bachmann , Udo Haas , Ulrike Altenburger , Ludwig Krueger , Margarete Krueger
发明人： Hanns-Christian Mahler , Hans-Peter Zobel , Robert Mueller , Christiane Bachmann , Udo Haas , Ulrike Altenburger , Ludwig Krueger , Margarete Krueger
IPC分类号： A61K9/19 , A61K39/395 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/26 , A61K47/34 , A61P35/00 , C07K16/28 , A61K31/7008 , A61K31/7012
CPC分类号： C07K16/2863 , A61K9/0019 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/26 , A61K2039/505
摘要： The invention relates to a lyophilised pharmaceutical preparation comprising an antibody against the endothelial growth factor receptor (EGF receptor). The preparation has increased storage stability, even at elevated temperatures, and, after reconstitution, can be used parenterally for the treatment of tumours.
摘要翻译：本发明涉及包含针对内皮生长因子受体（EGF受体）的抗体的冻干药物制剂。该制剂即使在升高的温度下也具有增加的储存稳定性，并且在重构后，可以肠胃外用于治疗肿瘤。

6. 发明申请

US20050175611A1 Pharmaceutical preparation comprising an antibody against the EGF receptor 审中-公开
标题翻译：包含针对EGF受体的抗体的药物制剂
公开(公告)号：US20050175611A1
公开(公告)日：2005-08-11
申请号：US10996597
申请日：2004-11-26
申请人： Hanns-Christian Mahler , Robert Mueller
发明人： Hanns-Christian Mahler , Robert Mueller
IPC分类号： A61K9/00 , A61K9/08 , A61K39/395 , A61K47/02 , A61K47/06 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/26 , A61K47/30 , A61K47/32 , C07K16/28 , A61K31/198 , A61K31/4172
CPC分类号： A61K47/10 , A61K9/0019 , A61K39/39591 , A61K47/02 , A61K47/12 , A61K47/183 , A61K47/26 , C07K16/2863 , C07K2317/24
摘要： The invention relates to an aqueous pharmaceutical preparation comprising an antibody against endothelial growth factor receptor (EGF receptor). The preparation has increased storage stability, even at elevated temperatures, and can be used for the treatment of tumours.
摘要翻译：本发明涉及包含抗内皮生长因子受体（EGF受体）抗体的水性药物制剂。该制剂即使在升高的温度下也具有增加的储存稳定性，并可用于治疗肿瘤。

7. 发明申请

US20120018338A1 METHOD FOR AVOIDING GLASS FOGGING 审中-公开
标题翻译：避免玻璃雾化的方法
公开(公告)号：US20120018338A1
公开(公告)日：2012-01-26
申请号：US13262603
申请日：2010-03-26
申请人： Isabelle Bauer Dauphin , Hanns-Christian Mahler
发明人： Isabelle Bauer Dauphin , Hanns-Christian Mahler
IPC分类号： B65D85/00 , F26B5/06
CPC分类号： A61K9/19 , A61J1/00 , A61K31/00 , A61L2/16
摘要： The present invention relates to the use of a glass container having a contact angle of more than about 10° for preventing glass fogging during freeze drying of a pharmaceutical composition. The pharmaceutical composition comprises a therapeutic agent and a surfactant. The respective glass container and a method for freeze drying the pharmaceutical composition are also disclosed.
摘要翻译：本发明涉及一种接触角大于约10°的玻璃容器的用途，用于防止药物组合物冷冻干燥期间的玻璃雾化。药物组合物包含治疗剂和表面活性剂。还公开了相应的玻璃容器和用于冷冻干燥药物组合物的方法。

8. 发明申请

US20080166346A1 Lyophilised Preparation Comprising Antibodies Against The EFG Receptor 审中-公开
标题翻译：包含EFG受体抗体的冻干制剂
公开(公告)号：US20080166346A1
公开(公告)日：2008-07-10
申请号：US12051436
申请日：2008-03-19
申请人： Hanns-Christian Mahler , Hans-Peter Zobel , Robert Muller , Christiane Bachmann , Udo Haas , Margarete (heir Ludwig Kruger) Kruger , Ulrike Martini-Marr
发明人： Hanns-Christian Mahler , Hans-Peter Zobel , Robert Muller , Christiane Bachmann , Udo Haas , Margarete (heir Ludwig Kruger) Kruger , Ulrike Martini-Marr
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/2863 , A61K9/0019 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/26 , A61K2039/505
摘要： The invention relates to a lyophilised pharmaceutical preparation comprising an antibody against the endothelial growth factor receptor (EGF receptor). The preparation has increased storage stability, even at elevated temperatures, and, after reconstitution, can be used parenterally for the treatment of tumours.
摘要翻译：本发明涉及包含针对内皮生长因子受体（EGF受体）的抗体的冻干药物制剂。该制剂即使在升高的温度下也具有增加的储存稳定性，并且在重构后，可以肠胃外用于治疗肿瘤。

9. 发明申请

US20070299139A1 Lyophilisate Comprising N-Diaminomethylene-2-Methyl-4,5-Di(Methylsulfonyl)Benzamide 审中-公开
标题翻译：含有N-二氨基亚甲基-2-甲基-4,5-二（甲基磺酰基）苯甲酰胺的嗜热菌素
公开(公告)号：US20070299139A1
公开(公告)日：2007-12-27
申请号：US11575741
申请日：2005-09-10
申请人： Hanns-Christian Mahler , Rita Heckmann , Dorothee Kress , Dirk Schiroky
发明人： Hanns-Christian Mahler , Rita Heckmann , Dorothee Kress , Dirk Schiroky
IPC分类号： A61K31/166 , A61P9/10 , C07C211/44
CPC分类号： A61K9/19 , A61K9/0019 , A61K31/18 , A61K47/26 , C07C317/44
摘要： The invention relates to a lyophilisate comprising N-diaminomethylene-2-methyl-4,5di(methylsulfonyl)benzamide as active compound. The composition has increased storage stability, even at elevated temperatures, and can be administered parenterally as medicament after reconstitution.
摘要翻译：本发明涉及包含N-二氨基亚甲基-2-甲基-4,5-二（甲基磺酰基）苯甲酰胺作为活性化合物的冻干物。即使在升高的温度下，组合物也具有提高的储存稳定性，并且可以在重建后作为药物肠胃外给药。

10. 发明申请

US20070172475A1 Highly concentrated, liquid formulations of anti-egfr antibodies 审中-公开
标题翻译：高度浓缩的抗egfr抗体的液体制剂
公开(公告)号：US20070172475A1
公开(公告)日：2007-07-26
申请号：US10588458
申请日：2005-01-27
申请人： Susanne Matheus , Hanns-Christian Mahler
发明人： Susanne Matheus , Hanns-Christian Mahler
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： A61K9/08 , C07K16/2863
摘要： The invention relates to processes for the preparation of highly concentrated, liquid formulations comprising at least one anti-EGFR antibody and/or one of its variants and/or fragments, in particular monoclonal antibodies against the EGF receptor, particularly preferably of Mab C225 (cetuximab) and Mab h425 (EMD 72000), by ultrafiltration. The invention furthermore relates to highly concentrated, liquid formulations of anti-EGFR antibodies, in particular of monoclonal antibodies against the EGF receptor, particularly preferably Mab C225 (cetuximab) and Mab h425 (EMD 72000) and/or variants and/or fragments thereof, characterised in that the highly concentrated, liquid formulations have a content of anti-EGFR antibodies of 10-250, preferably 50-180 mg/ml, particularly preferably of 100-150 mg/ml, and to the use thereof.
摘要翻译：本发明涉及用于制备高浓度液体制剂的方法，其包含至少一种抗EGFR抗体和/或其变体和/或片段之一，特别是抗EGF受体的单克隆抗体，特别优选Mab C225（西妥昔单抗）和Mab h425（EMD 72000），通过超滤。本发明还涉及高度浓缩的抗EGFR抗体制剂，特别是抗EGF受体的单克隆抗体，特别优选Mab C225（西妥昔单抗）和Mab h425（EMD 72000）和/或其变体和/或片段，其特征在于高度浓缩的液体制剂具有10-250，优选50-180mg / ml，特别优选100-150mg / ml的抗EGFR抗体含量及其用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式